MX2022006299A - Proteína inmunogénica contra una infección gonocócica. - Google Patents
Proteína inmunogénica contra una infección gonocócica.Info
- Publication number
- MX2022006299A MX2022006299A MX2022006299A MX2022006299A MX2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic protein
- protein against
- gonococcal infection
- against gonococcal
- seq
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 206010018612 Gonorrhoea Diseases 0.000 title 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 abstract 2
- 108700007374 Neisseria meningitidis NHBA Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere, entre otras cosas, a un fragmento inmunogénico de una proteína del antígeno de unión a heparina neisserial (NHBA) de Neisseria gonorrhoeae (SEQ ID NO: 1) para la prevención y el tratamiento de enfermedades y afecciones gonocócicas o meningocócicas asociadas de Neisseria gonorrhoeae. En algunas modalidades, el fragmento inmunogénico corresponde a un fragmento C terminal de la proteína (SEQ ID NO: 2).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019904450A AU2019904450A0 (en) | 2019-11-25 | Immunogenic protein against gonococcal infection | |
| PCT/AU2020/051257 WO2021102505A1 (en) | 2019-11-25 | 2020-11-20 | Immunogenic protein against gonococcal infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006299A true MX2022006299A (es) | 2023-01-19 |
Family
ID=76128579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006299A MX2022006299A (es) | 2019-11-25 | 2020-11-20 | Proteína inmunogénica contra una infección gonocócica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181709A1 (es) |
| EP (1) | EP4065595A4 (es) |
| JP (1) | JP2023503963A (es) |
| KR (1) | KR20220152402A (es) |
| CN (1) | CN115348968A (es) |
| AU (1) | AU2020390430A1 (es) |
| BR (1) | BR112022010167A2 (es) |
| CA (1) | CA3162559A1 (es) |
| MX (1) | MX2022006299A (es) |
| WO (1) | WO2021102505A1 (es) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047238A (en) | 1983-06-15 | 1991-09-10 | American Home Products Corporation | Adjuvants for vaccines |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5811105A (en) | 1987-12-23 | 1998-09-22 | Glaxo Wellcome, Inc. | Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| GB8912330D0 (en) | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| WO2016008961A1 (en) * | 2014-07-17 | 2016-01-21 | Glaxosmithkline Biologicals S.A. | Meningococcus vaccines |
| CN106606775A (zh) | 2015-10-27 | 2017-05-03 | 格里菲斯大学 | 脂质体a群链球菌疫苗 |
| US20180064801A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
-
2020
- 2020-11-20 CA CA3162559A patent/CA3162559A1/en active Pending
- 2020-11-20 EP EP20894367.0A patent/EP4065595A4/en active Pending
- 2020-11-20 BR BR112022010167A patent/BR112022010167A2/pt unknown
- 2020-11-20 US US17/779,411 patent/US20230181709A1/en active Pending
- 2020-11-20 WO PCT/AU2020/051257 patent/WO2021102505A1/en unknown
- 2020-11-20 JP JP2022530318A patent/JP2023503963A/ja active Pending
- 2020-11-20 AU AU2020390430A patent/AU2020390430A1/en active Pending
- 2020-11-20 CN CN202080094488.2A patent/CN115348968A/zh active Pending
- 2020-11-20 MX MX2022006299A patent/MX2022006299A/es unknown
- 2020-11-20 KR KR1020227021629A patent/KR20220152402A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4065595A1 (en) | 2022-10-05 |
| CN115348968A (zh) | 2022-11-15 |
| BR112022010167A2 (pt) | 2022-08-09 |
| KR20220152402A (ko) | 2022-11-15 |
| EP4065595A4 (en) | 2023-12-20 |
| US20230181709A1 (en) | 2023-06-15 |
| JP2023503963A (ja) | 2023-02-01 |
| CA3162559A1 (en) | 2021-06-03 |
| WO2021102505A1 (en) | 2021-06-03 |
| AU2020390430A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009086539A3 (en) | Treatment and prophylaxis of amyloidosis | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| MX2009006760A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas. | |
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| WO2000066741A3 (en) | Conserved neisserial antigens | |
| NZ599193A (en) | Siglec 15 antibodies in treating bone loss-related disease | |
| UA111141C2 (uk) | Рекомбінантні антигени рсв | |
| NZ598063A (en) | Gram-positive bacteria specific binding compounds | |
| UA87128C2 (ru) | ИММУНОГЛОБУЛИН АНТИ-EрCAM И СПОСОБ ЕГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| WO2009152147A3 (en) | Compositions and methods for dengue virus (dv) treatment and vaccination | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| ZA202107428B (en) | Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof | |
| SG170804A1 (en) | Pseudomonas aeruginosa outer membrane protein pa0427 | |
| MX2022003820A (es) | Metodos de tratamiento para modificar la hermodinamica. | |
| WO2019081595A3 (en) | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | |
| ZA202110285B (en) | Antibodies and methods of use | |
| MX2022006299A (es) | Proteína inmunogénica contra una infección gonocócica. | |
| AU2018244677A1 (en) | Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane | |
| MX2023013335A (es) | Anticuerpos anti-tigit y usos de los mismos. | |
| CY1115541T1 (el) | Μεταλλαγμενη πρωτεϊνη τατ ουι για την προληψη ή την θεραπευτικη αντιμετωπιση του αids | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| MX2022009661A (es) | Tratamiento de enfermedades asociadas a panx1. | |
| NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella |